Biogen Idec Buys Complete Ownership of Tysabri® from Elan
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 2 (Table of Contents)
Published: 16 Feb-2013
DOI: 10.3833/pdr.v2013.i2.1897 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Biogen Idec is to acquire full rights to the multiple sclerosis (MS) therapy Tysabri® (natalizumab) from its 50/50 collaborator Elan...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS